An experimental treatment targeting hepatitis C was able to inhibit replication of the virus in the bloodstream of chimpanzees and could treat chronic infections in humans, a new study said Thursday.
The treatment works by inhibiting a molecule that helps hepatitis C virus replicate, according to scientists at the Southwest Foundation for Biomedical Research (SFBR), who said the drug continued to work up to several months after it was used.
The treatment is already undergoing "human clinical trials and is currently undergoing Phase 1 clinical studies in healthy volunteers," the researchers said in a press release.
It is the first medication of its type to be tested on humans, according to the researchers, whose work was published in the December 3 issue of the journal Science Express.
The medication, dubbed SPC3649, was developed by the biopharmaceutical firm Santaris Pharma A/S, a Danish company.
It uses Santaris' proprietary nucleic acid called "locked nucleic acid," which captures the microRNA122 molecule that the hepatitis C virus (HCV) would otherwise use to replicate.
"Our collaboration with Santaris Pharma proved that the drug worked exceptionally well in treating HCV infections in chimpanzees," said SFBR's Robert Lanford, the lead author of the research.
The study also showed the technology could prove useful in the treatment of other diseases, including HIV, cancer and inflammatory diseases.
According to the World Health Organization (WHO), 170 million people worldwide are infected with hepatitis C, which is transmitted via blood and can progress over years into cirrhosis and liver cancer.